Epigenomics Finally Gains FDA Approval For Epi proColon Blood Test

14 Apr 2016

Executive Summary

Epigenomics has finally gained US FDA approval for its Epi proColon noninvasive colorectal cancer screening test, ending what has been a long, obstacle-filled journey for the German-US molecular diagnostics company.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

Topics

Germany

North America

United States

Subjects
Innovation

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Medical Device Germany United States

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT036009

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT036009

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Epigenomics Finally Gains FDA Approval For Epi proColon Blood Test

Executive Summary

Related Content

Exact Sciences Launches First Stool-Based DNA Screening Test For Colorectal Cancer

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert